Treatment of infertility in women with pituitary tumors

Expert Review of Anticancer Therapy

Volumn 6, Issue 9 SUPPL., 2006, Pages

  Hirshfeld Cytron, Jennifer ^a   Kim, Helen H ^b  

^a Department of Obstetrics and Gynecology ^*  (United States)

^b Reprod Endocrinol/Infertility Sec   (United States)

Author keywords

Assisted reproduction; Dopamine agonists; Follicle stimulating hormone; Gonadotropins; Human chorionic gonadotropin; Hyperprolactinemia; In vitro fertilization; Infertility; Luteinzing hormone; Pituitary adenoma

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CLOMIFENE CITRATE; CORTICOTROPIN; DOPAMINE RECEPTOR STIMULATING AGENT; FOLLITROPIN; GONADOTROPIN; GROWTH HORMONE; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROLACTIN; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE; THYROTROPIN;

ABDOMINAL PAIN; ARTIFICIAL INSEMINATION; CHO CELL; CLINICAL PROTOCOL; CONGENITAL MALFORMATION; CONSTIPATION; DIZZINESS; DRUG WITHDRAWAL; ECTOPIC PREGNANCY; EMBRYO TRANSFER; FATIGUE; FEMALE; FEMALE FERTILITY; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GONAD DYSFUNCTION; GONAD FUNCTION; HEADACHE; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; HYPOPITUITARISM; INDIVIDUALIZATION; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; INTRAUTERINE INSEMINATION; MEDICAL DECISION MAKING; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MULTIPLE PREGNANCY; MUSCLE WEAKNESS; NAUSEA; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PATIENT COUNSELING; POSTOPERATIVE PERIOD; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY RATE; PROLACTINOMA; RECOMBINANT DNA TECHNOLOGY; REVIEW; SMALL FOR DATE INFANT; SPONTANEOUS ABORTION; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT OUTCOME; TUMOR VOLUME; VERTIGO;

DOPAMINE AGONISTS; FEMALE; GONADOTROPINS; HUMANS; INFERTILITY; PITUITARY NEOPLASMS; PREGNANCY; REPRODUCTIVE TECHNIQUES, ASSISTED;

EID: 33750081413     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.9.S55     Document Type: Review

References (53)

1. Bronstein MD, Salgado LR, de Castro Musolino NR. Medical management of pituitary adenomas: the special case of management of the pregnant woman. Pituitary 5(2), 99-107 (2002).
2. Mortini P, Losa M, Barzaghi R, Boari N, Giovanelli M. Results of transsphenoidal surgery in a large series of patients with pituitary adenoma. Neurosurgery 56(6), 1222-1233 (2005).
3. Swensen R, Kirsch W. Brain neoplasms in women: a review. Clin. Obstet. Gynecol. 45(3), 904-927 (2002).
4. Speroff L, Fritz MA. Regulation of the Menstrual Cycle. In: Clinical Gynecologic Endocrinology and Infertility. Speroff L, Fritz MA (Eds). Lippincott Williams & Wilkins, PA, USA 187-232 (2005).
5. Yazigi RA, Quintero CH, Salameh WA. Prolactin disorders. Fertil. Steril. 67(2), 215-225 (1997).
6. Arita K, Uozumi T, Yano T et al. Effect of surgery on gonadal function of premenopausal women with pituitary adenomas other than prolactinomas. Endocr. J. 43(2), 131-138 (1996).
7. Schlechte JA. Clinical practice. Prolactinoma. N. Engl. J. Med. 349(21), 2035-2041 (2003).
8. Vance ML, Evans WS, Thorner MO. Drugs five years later. Bromocriptine. Ann. Intern. Med. 100(1), 78-91 (1984).
9. Molitch ME. Management of prolactinomas. Ann. Rev. Med. 40 225-232 (1989).
10. Molitch ME. Pituitary tumors and pregnancy. Growth Horm. IGF Res. 13(Suppl. A), S38-S44 (2003).
11. Liu C, Tyrrell JB. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy. Pituitary 4(3), 179-185 (2001).
12. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N. Engl. J. Med. 331(14), 904-909 (1994).
13. Serri O. Progress in the management of hyperprolactinemia. N. Engl. J. Med. 331(14), 942-944 (1994).
14. Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod. Toxicol. 10(4), 333-337 (1996).
15. Verhelst J, Abs R, Maiter D et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J. Clin. Endocrinol. Metab. 84(7), 2518-2522 (1999).
16. Ricci F, Parazzini F, Motta T et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod. Toxicol. 16(6), 791-793 (2002).
17. Ciccarelli E, Grottoli S, Razzore P et al. Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. J. Endocrinol. Invest. 20(9), 547-551 (1997).
18. Nomikos P, Ladar C, Fahlbusch R, Buchfelder M. Impact of primary surgery on pituitary function in patients with nonfunctioning pituitary adenomas - a study on 721 patients. Acta Neurochir. (Wien). 146(1), 27-35 (2004).
19. Speroff L, Fritz MA. Induction of Ovulation. In: Clinical Gynecologic Endocrinology and Infertility. Speroff L, Fritz MA. (Eds). Lippincott Williams & Wilkins, PA, USA 1175-1213 (2005).
20. Lunenfeld B. Historical perspectives in gonadotrophin therapy. Hum. Reprod. Update 10(6), 453-467 (2004).
21. Claman P, Wilkie V, Collins D. Timing intrauterine insemination either 33 or 39 hours after administration of human chorionic gonadotropin yields the same pregnancy rates as after superovulation therapy. Fertil. Steril. 82(1), 13-16 (2004).
22. Dor J, Itzkowic DJ, Mashiach S, Lunenfeld B, Serr DM. Cumulative conception rates following gonadotropin therapy. Am. J. Obstet. Gynecol. 136(1), 102-105 (1980).
23. Fluker MR, Urman B, Mackinnon M, Barrow SR, Pride SM, Yuen BH. Exogenous gonadotropin therapy in World Health Organization groups I and II ovulatory disorders. Obstet. Gynecol. 83(2), 189-196 (1994).
24. American Society for Reproductive Medicine. Patient Fact Sheet: Side Fffects of Gonadotropins. ASRM, AL, USA (2005).
25. ASRM. Ovarian hyperstimulation syndrome. Fertil. Steril. 80(5), 1309-1314 (2003).
26. ASRM. Multiple pregnancy associated with infertility therapy. Fertil. Steril. 82(Suppl. 1) S153-S157 (2004).
27. Dickey RP, Taylor SN, Lu PY, Sartor BM, Rye PH, Pyrzak R. Risk factors for high-order multiple pregnancy and multiple birth after controlled ovarian hyperstimulation: results of 4,062 intrauterine insemination cycles. Fertil. Steril. 83(3), 671-683 (2005).
28. Gleicher N, Oleske DM, Tur-Kaspa I, Vidali A, Karande V. Reducing the risk of high-order multiple pregnancy after ovarian stimulation with gonadotropins. N. Engl. J. Med. 343(1), 2-7 (2000).
29. Rebar RW, DeCherney AH. Assisted reproductive technology in the United States. N. Engl. J. Med. 350(16), 1603-1604 (2004).
30. Speroff L, Fritz MA. Assisted Reproductive Technologies. In: Clinical Gynecologic Endocrinology and Infertility. Speroff L, Fritz MA (Eds). Lippincott Williams & Wilkins, PA, USA 1216-1274 (2005).
31. Palermo GD, Cohen J, Alikani M, Adler A, Rosenwaks Z. Intracytoplasmic sperm injection: a novel treatment for all forms of male factor infertility. Fertil. Steril. 63(6), 1231-1240 (1995).
32. US Centers for Disease Contol and Prevention. Assisted Reproductive Technology (ART) Report. CDC, GA, USA (2003).
33. Zorn B, Pfeifer M, Virant-Klun I, Meden-Vrtovec H. Intracytoplasmic sperm injection as a complement to gonadotrophin treatment in infertile men with hypogonadotrophic hypogonadism. Int J Androl. 28(4), 202-207 (2005).
34. ASRM Guidelines on the number of embryos transferred. Fertil. Steril. 82(3), 773-774 (2004).
35. Daly AF, Jaffrain-Rea ML, Beckers A. Clinical and genetic features of familial pituitary adenomas. Horm. Metab. Res. 37(6), 347-354 (2005).
36. ASRM. Preimplantation genetic diagnosis. Fertil. Steril. 82(Suppl. 1) S120-S122 (2004).
37. Simpson JL, Carson SA, Cisneros P. Preimplantation genetic diagnosis (PGD) for heritable neoplasia. J. Natl Cancer Inst. Monogr. 34, 87-90 (2005).
38. Kearns WG, Pen R, Graham J et al. Preimplantation genetic diagnosis and screening. Semin. Reprod. Med. 23(4), 336-347 (2005).
39. Klemetti R, Sevon T, Gissler M, Hemminki E. Complications of IVF and ovulation induction. Hum Reprod. 20(12), 3293-3300 (2005).
40. American Society for Reproductive Medicine. Assisted Reproductive Technologies: A Guide for Patients. ASRM, AL, USA (2003).
41. Olson CK, Keppler-Noreuil KM, Romitti PA et al. In vitro fertilization is associated with an increase in major birth defects. Fertil. Steril. 84(5), 1308-1315 (2005).
42. Klemetti R, Gissler M, Sevon T, Koivurova S, Ritvanen A, Hemminki E. Children born after assisted fertilization have an increased rate of major congenital anomalies. Fertil. Steril. 84(5), 1300-1307 (2005).
43. Allen C, Reardon W. Assisted reproduction technology and defects of genomic imprinting. BJOG 112(12), 1589-1594 (2005).
44. Maher ER. Imprinting and assisted reproductive technology. Hum. Mol. Genet. 14(Spec No 1), R133-R138 (2005).
45. Schieve LA, Meikle SF, Ferre C, Peterson HB, Jeng G, Wilcox LS. Low and very low birth weight in infants conceived with use of assisted reproductive technology. N. Engl. J. Med. 346(10), 731-737 (2002).
46. Iwasaki Y, Oiso Y, Kondo K et al. Aggravation of subclinical diabetes insipidus during pregnancy. N. Engl. J. Med. 324(8), 522-526 (1991).
47. Brewster UC, Hayslett JP. Diabetes insipidus in the third trimester of pregnancy. Obstet. Gynecol. 105(5 Pt 2), 1173-1176 (2005).
48. Overton CE, Davis CJ, West C, Davies MC, Conway GS. High risk pregnancies in hypopituitary women. Hum Reprod. 17(6), 1464-1467 (2002).
49. Kitajima Y, Endo T, Yamazaki K, Hayashi T, Kudo R. Successful twin pregnancy in panhypopituitarism caused by suprasellar germinoma. Obstet. Gynecol. 102(5 Pt 2), 1205-1207 (2003).
50. Kriplani A, Goswami D, Agarwal N, Bhatla N, Ammini AC. Twin pregnancy following gonadotrophin therapy in a patient with Sheehan's syndrome. Int. J. Gynaecol. Obstet. 71(1), 59-63 (2000).
51. Volz J, Heinrich U, Volz-Koster S. Conception and spontaneous delivery after total hypophysectomy. Fertil. Steril. 77(3), 624-625 (2002).
52. Salle A, Klein M, Pascal-Vigneron V, Dousset B, Leclere J, Weryha G. Successful pregnancy and birth after sequential cotreatment with growth hormone and gonadotropins in a woman with panhypopituitarism: a new treatment protocol. Fertil. Steril. 74(6), 1248-1250 (2000).
53. Voutetakis A, Sertedaki A, Livadas S et al. Ovulation induction and successful pregnancy outcome in two patients with Prop1 gene mutations. Fertil. Steril. 82(2), 454-457 (2004).